Proactive Investors - Run By Investors For Investors

Soleno stock price triples as safety board gives go-ahead to continue Prader-Willi trial

The Data Safety Monitoring Board has recommended that the trial known as DESTINY PWS continue without changes
Scientist with test tubes
The company said it was continuing to enroll patients

Soleno Therapeutics Inc (NASDAQ:SLNOW) tripled in Friday's Nasdaq trading as the biopharma company received good news about its Phase 3 trial on a tablet for Prader-Willi syndrome (PWS).

The Data Safety Monitoring Board (DSMB) has recommended that the trial known as DESTINY PWS for the diazoxide choline controlled-release tablet continue without any changes. 

Shares in Soleno surged 223% on the Nasdaq index to $4.36.

READ: Soleno Therapeutics shares surge on positive patent news

The hallmark symptom of PWS is hyperphagia, a chronic feeling of insatiable hunger. Patients can also suffer from behavioral problems, cognitive disabilities, low muscle tone, excess body fat and incomplete sexual development.

“We are delighted with the DSMB’s positive recommendation to continue the Phase 3 trial as planned as it further supports DCCR’s safety profile,” Dr Anish Bhatnagar, CEO at Soleno, said in a statement. "We are continuing to enrol patients with 14 sites activated in DESTINY PWS."

He added that patients continue to roll over into C602, the nine-month, open-label safety extension study for patients completing treatment in the DESTINY PWS study. 

The DESTINY PWS trial is a randomized, double-blind, placebo-controlled study of once-daily oral administration of DCCR in about 100 patients with a confirmed diagnosis of PWS.

Diazoxide choline has received orphan drug designation for the treatment of PWS in the US and EU.

Contact Giles at [email protected]

Follow him on Twitter @Gile74

View full SLNOW profile View Profile

Related Articles

1550850611_CancerHeadline.jpg
February 22 2019
Broker Hybridan reckons Sareum is “arguably a bargain target for the relatively large group of biotech and pharma companies interested in TYK2 and the wider JAK inhibitor space”
young girl with allergy
February 15 2019
Allergy Therapeutics is a long-established specialist in the prevention, diagnosis and treatment of allergies
1537236236_main-better-use.jpg
September 17 2018
The company is utilising technology and big data to tackle the growing healthcare crisis and personalise treatment options for preventative care.
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use